

2018 Conflict of Interest Disclosure Form

Do you or your spouse combined have an equity interest such as ownership interest, stock options (excluding mutual funds), or any other equity interest in a commercial business in the health care field?

Yes

Please describe in detail

Stock options with Ironshore; In the past year, Dr. Faraone received income, potential income, travel expenses continuing education support and/or research support from Lundbeck, Rhodes, Arbor, KenPharm, Ironshore, Shire, Akili Interactive Labs, CogCubed, Alcobra, VAYA, Sunovion, Genomind and Neurolifesciences. With his institution, he has US patent US20130217707 A1 for the use of sodium-hydrogen exchange inhibitors in the treatment of ADHD. In previous years, he received support from: Shire, Neurovance, Alcobra, Otsuka, McNeil, Janssen, Novartis, Pfizer and Eli Lilly. Dr. Faraone receives royalties from books published by Guilford Press: Straight Talk about Your Child's Mental Health, Oxford University Press: Schizophrenia: The Facts and Elsevier: ADHD: Non-Pharmacologic Interventions. He is principal investigator of www.adhdinadults.com.

Have you or your spouse received payments as compensation for advisory board participation, consultation with any commercial business in the health care field, speakers bureau participation, grants to fund research? If yes, please explain.

Yes

Advisory Board

Yes

Advisory Board

Akili Advisory Board
Alcobra Advisory Board
IronShore Advisory Board
Shire Advisory Board
Arbor Advisory Board
Lundbeck and Takeda Advisory Board
KenPharm Advisory Board

Consultation

Yes

Consultation

Akili Consultant
Vaya Consultant
Ironshore Consultant

Speakers Bureau

No

Research Grants

Yes

Research Grants

Shire Research Grant PI

Otsuka Research Grant PI

Arbor Research Grant PI

Sunovion Research Grant PI

NIH Research Grant PI

European Commission Research Grant PI